ADHD News & Research

ADHD Medication Update: New Clinical Data for Dyanavel XR

At a recent neuroscience conference, the manufacturer of Dyanavel XR presented four posters regarding the stimulant medication’s extended release oral suspension mechanism that suggest it takes effect within 30 minutes, lasts up to 13 hours, and helps to reduce ADHD symptoms in patients aged 6 and older.

November 19, 2018

Last week, the maker of Dyanavel XR presented new research that demonstrates the liquid stimulant medication is effective in reducing symptoms of attention deficit disorder (ADHD or ADD) in patients aged 6 and older for up to 13 hours with a sustained release.

Tris Pharma, Inc., the biopharmaceutical company that manufactures Dyanavel XR, presented four scientific posters at the recent 2018 Neuroscience Education Institute (NEI) Congress in Orlando, Florida, evaluating the efficacy, safety, and programmability of its Amphetamine Extended-Release Oral Suspension (AMPH EROS).

The posters indicated that AMPH EROS was effective in reducing ADHD symptoms as early as 30 minutes post-dose, and from 1 to 13 hours after dosing. It was also shown to be effective in reducing ADHD symptoms in the open-label dose optimization phase of a pivotal laboratory classroom study.

A separate poster asserted that the release characteristics of Dyanavel XR’s patented drug delivery technology, LiquiXR, are programmable, allowing for customized sustained release of amphetamine.

Barry K. Herman, M.D, M.M.M., Senior Vice President and Chief Medical Officer of Tris stated that the data presented “underscore Tris’ commitment to furthering research in and advancing the treatment of ADHD.”

In the three posters pertaining to AMPH EROS, the adverse effects reported were consistent with those of other amphetamine products.